STAGE III LUNG CANCER AJCC V8
Clinical trials for STAGE III LUNG CANCER AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new STAGE III LUNG CANCER AJCC V8 trials appear
Sign up with your email to follow new studies for STAGE III LUNG CANCER AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo approach for lung cancer patients who can't have surgery
Disease control OngoingThis study tests a two-step treatment for people with stage II or III non-small cell lung cancer who are not healthy enough for surgery. First, they receive a shorter, higher-dose course of radiation. Then they get an immunotherapy drug called atezolizumab to help their immune sy…
Matched conditions: STAGE III LUNG CANCER AJCC V8
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 16, 2026 22:50 UTC
-
Immunotherapy combo shows promise in lung cancer trial
Disease control OngoingThis study tests whether adding the immunotherapy drug atezolizumab to standard chemoradiation helps people with limited stage small cell lung cancer live longer. About 544 participants will receive either chemoradiation alone or chemoradiation plus atezolizumab. The goal is to s…
Matched conditions: STAGE III LUNG CANCER AJCC V8
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 16, 2026 12:53 UTC
-
New combo therapy shows promise for HIV patients with advanced cancer
Disease control OngoingThis early-phase trial tested the safety of combining two drugs, nivolumab and cabozantinib, in 8 people with HIV who also have advanced solid tumors. The goal was to see if the combination is safe and can shrink or stabilize the cancer. The study focused on finding the right dos…
Matched conditions: STAGE III LUNG CANCER AJCC V8
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 16, 2026 12:53 UTC
-
Lung cancer trial aims to boost survival with immunotherapy combo
Disease control OngoingThis study tests whether adding the immunotherapy drug durvalumab to standard chemoradiation, and continuing it afterward, helps people with stage III lung cancer that cannot be surgically removed live longer and keep the cancer from coming back. About 660 adults with newly diagn…
Matched conditions: STAGE III LUNG CANCER AJCC V8
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 16, 2026 12:52 UTC
-
New drug combo targets Hard-to-Treat cancers in early trial
Disease control OngoingThis early-phase study tests a new drug (M6620) combined with a standard chemotherapy (irinotecan) in adults with advanced solid tumors that have spread or can't be removed. The main goal is to find the safest dose and check for side effects. About 66 people with cancers like col…
Matched conditions: STAGE III LUNG CANCER AJCC V8
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 15, 2026 19:09 UTC
-
Immunotherapy duo plus radiation shows promise in lung cancer trial
Disease control OngoingThis early-phase trial studies the safety and effectiveness of combining two immunotherapy drugs (ipilimumab and nivolumab) with radiation therapy for patients with stage II or III non-small cell lung cancer that cannot be removed by surgery. The goal is to see if this combinatio…
Matched conditions: STAGE III LUNG CANCER AJCC V8
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 15, 2026 19:08 UTC
-
Triple-Drug cocktail shows promise for tough lung cancers
Disease control OngoingThis study tests a combination of three drugs (niraparib, temozolomide, and atezolizumab) in people with advanced solid tumors or extensive-stage small cell lung cancer that has responded to initial chemotherapy. The goal is to find the safest dose and see if the combination help…
Matched conditions: STAGE III LUNG CANCER AJCC V8
Phase: PHASE1, PHASE2 • Sponsor: Jonsson Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 15, 2026 19:08 UTC
-
Cancer vaccine plus immunotherapy shows promise in advanced lung and Head/Neck tumors
Disease control OngoingThis study tests a combination of the CIMAvax vaccine and nivolumab (an immunotherapy drug) in people with advanced non-small cell lung cancer or squamous head and neck cancer. The goal is to find the best dose and see if the combination helps control tumor growth and improve sur…
Matched conditions: STAGE III LUNG CANCER AJCC V8
Phase: PHASE1, PHASE2 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated Jun 15, 2026 19:06 UTC
-
Lung cancer treatment goes home: can telemedicine replace hospital visits?
Disease control OngoingThis study tests whether a lung cancer drug called atezolizumab can be safely given as a shot under the skin at home, with doctors monitoring patients through video calls. It involves 5 adults with non-small cell lung cancer. The goal is to see if this home-based approach is prac…
Matched conditions: STAGE III LUNG CANCER AJCC V8
Phase: PHASE2 • Sponsor: University of Southern California • Aim: Disease control
Last updated Jun 15, 2026 19:06 UTC
-
Heat vs scalpel: new study tests better way to treat lung lesions
Disease control OngoingThis study compares two treatments for lung tumors: microwave ablation (using heat to kill cancer cells) and surgical wedge resection (removing a small piece of lung). It includes adults with non-small cell lung cancer, sarcoma, or colorectal cancer that has spread to the lungs. …
Matched conditions: STAGE III LUNG CANCER AJCC V8
Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 15, 2026 19:05 UTC
-
New drug combo targets Hard-to-Treat cancers
Disease control OngoingThis early-stage trial tests a new drug (BAY 1895344) combined with standard chemotherapy for people with advanced solid tumors, especially bladder cancer. The goal is to find the safest dose and see how well the combination works. About 74 adults with cancers like lung, ovarian,…
Matched conditions: STAGE III LUNG CANCER AJCC V8
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 15, 2026 19:04 UTC
-
New combo aims to tame immunotherapy side effects in advanced cancers
Disease control OngoingThis study tests whether adding tocilizumab to standard immunotherapy (ipilimumab and nivolumab) can reduce severe side effects in people with advanced melanoma, lung cancer, or bladder cancer. About 35 participants will receive the combination to see if it is safer and still eff…
Matched conditions: STAGE III LUNG CANCER AJCC V8
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 15, 2026 18:56 UTC
-
Cord blood cells engineered to fight lung cancer in new trial
Disease control OngoingThis early-phase trial tests a new treatment for people with advanced non-small cell lung cancer that no longer responds to standard immunotherapy. The treatment uses immune cells from donated umbilical cord blood that are genetically modified to better recognize and attack cance…
Matched conditions: STAGE III LUNG CANCER AJCC V8
Phase: PHASE1 • Sponsor: University of California, Irvine • Aim: Disease control
Last updated Jun 15, 2026 18:55 UTC
-
New combo attack on tough lung cancer shows promise
Disease control OngoingThis study tests two drugs together—trametinib and pembrolizumab—in people with advanced non-small cell lung cancer that has returned or spread. The goal is to see if the combination can shrink tumors or slow the cancer's growth. About 37 participants will receive the treatment, …
Matched conditions: STAGE III LUNG CANCER AJCC V8
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 15, 2026 18:54 UTC
-
New combo targets hard-to-treat lung cancer in early trial
Disease control OngoingThis early-phase trial tests the safety and best dose of a new drug called minnelide when combined with the standard drug osimertinib for people with advanced EGFR-mutant non-small cell lung cancer. Only 8 participants are enrolled. The goal is to find side effects and the right …
Matched conditions: STAGE III LUNG CANCER AJCC V8
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 15, 2026 18:54 UTC
-
New drug duo aims to control aggressive lung and nerve cancers
Disease control OngoingThis study tests two drugs together for people with small cell lung cancer or other high-grade neuroendocrine cancers that have already been treated. Niraparib blocks a DNA repair protein in cancer cells, while dostarlimab helps the immune system attack the tumor. The goal is to …
Matched conditions: STAGE III LUNG CANCER AJCC V8
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 15, 2026 18:54 UTC
-
Radiation booster targets lung tumors that came back
Disease control OngoingThis early-stage trial tests a drug called NBTXR3 that makes radiation more effective at killing cancer cells. It is for people with non-small cell lung cancer that has returned and cannot be removed with surgery. The study aims to find the safest dose and see if combining the dr…
Matched conditions: STAGE III LUNG CANCER AJCC V8
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 12, 2026 12:07 UTC
-
New drug combo targets tough lung cancer in early trial
Disease control OngoingThis early-phase study tests a combination of two drugs, brigatinib and bevacizumab, in people with a specific type of lung cancer (ALK-positive) that has spread or returned after prior ALK-directed therapy. The main goals are to find the best dose and check for side effects. Onl…
Matched conditions: STAGE III LUNG CANCER AJCC V8
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 11, 2026 12:10 UTC
-
New combo therapy shows promise for tough lung cancer
Disease control OngoingThis study tests a new drug combination for people with a specific type of advanced lung cancer (EGFR-mutant non-small cell lung cancer). The two drugs, LY3295668 and osimertinib, work by blocking enzymes that help cancer cells grow. The goal is to find the safest dose and see if…
Matched conditions: STAGE III LUNG CANCER AJCC V8
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 10, 2026 13:28 UTC
-
New hope for cancer patients: drug targets appetite loss and wasting
Symptom relief OngoingThis study looks at whether a drug called anamorelin can help improve appetite and prevent weight loss in people with advanced non-small cell lung cancer who have lost their appetite and are losing weight. About 25 participants will take either the drug or a placebo and share the…
Matched conditions: STAGE III LUNG CANCER AJCC V8
Phase: PHASE2, PHASE3 • Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Jun 15, 2026 19:08 UTC
-
New online program aims to ease emotional burden for women battling lung cancer
Symptom relief OngoingThis study tests an online program designed to help women with lung cancer feel more supported and less distressed during treatment. The program uses techniques like mindfulness and emotional processing to improve social well-being. About 70 women with stage I-IV non-small cell l…
Matched conditions: STAGE III LUNG CANCER AJCC V8
Phase: NA • Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Jun 15, 2026 18:57 UTC
-
Smart radiation planning may ease lung cancer treatment side effects
Symptom relief OngoingThis study looks at whether updating radiation treatment plans at set times (adaptive planning) can lower side effects like lung inflammation in people with stage II-IV non-small cell lung cancer. About 34 participants will receive standard radiation and immunotherapy, but their …
Matched conditions: STAGE III LUNG CANCER AJCC V8
Phase: NA • Sponsor: Rutgers, The State University of New Jersey • Aim: Symptom relief
Last updated Jun 12, 2026 12:04 UTC
-
New study tests online coaching to improve life after cancer treatment
Symptom relief OngoingThis study tests a telehealth self-management program for people who have finished treatment for early-stage lung or colorectal cancer. The program provides coaching on follow-up care, communication with doctors, and quality of life. Researchers will compare outcomes between part…
Matched conditions: STAGE III LUNG CANCER AJCC V8
Phase: PHASE3 • Sponsor: City of Hope Medical Center • Aim: Symptom relief
Last updated Jun 09, 2026 12:09 UTC
-
New Nurse-Led program aims to ease fear in advanced cancer patients
Symptom relief OngoingThis study tests a nurse-led program designed to help people with advanced lung or gynecologic cancer cope with fears about their future. About 42 participants will try the program, which includes sessions and home activities. The goal is to see if the program is practical and he…
Matched conditions: STAGE III LUNG CANCER AJCC V8
Phase: NA • Sponsor: City of Hope Medical Center • Aim: Symptom relief
Last updated Jun 05, 2026 12:07 UTC
-
One-and-Done radiation: a new hope for lung cancer patients after surgery?
Symptom relief OngoingThis early-stage study tests whether giving a single, very focused dose of radiation after lung cancer surgery is safe and causes fewer side effects than standard weeks-long radiation. It involves 50 adults with non-small cell lung cancer who had surgery but still have cancer cel…
Matched conditions: STAGE III LUNG CANCER AJCC V8
Phase: PHASE1 • Sponsor: Roswell Park Cancer Institute • Aim: Symptom relief
Last updated Jun 01, 2026 17:55 UTC
-
Massive biobank aims to unlock Cancer's secrets
Knowledge-focused OngoingThis study collects tissue and blood samples, along with medical information, from 1,600 people with various advanced cancers. Researchers will track these samples over time to learn how cancer changes and why some treatments stop working. The goal is to build a resource for futu…
Matched conditions: STAGE III LUNG CANCER AJCC V8
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Jun 15, 2026 18:55 UTC
-
New tool helps lung cancer patients take charge of their treatment choices
Knowledge-focused OngoingThis study is testing a low-literacy conversation tool designed to help people with lung cancer and their doctors make treatment decisions together. About 98 adults with non-small cell lung cancer will use the tool and report on their anxiety, decision confidence, and satisfactio…
Matched conditions: STAGE III LUNG CANCER AJCC V8
Phase: NA • Sponsor: OHSU Knight Cancer Institute • Aim: Knowledge-focused
Last updated Jun 11, 2026 12:12 UTC
-
Can we predict who will get nerve damage from chemo?
Knowledge-focused OngoingThis study aims to find out why some cancer patients develop nerve damage (tingling or numbness in hands and feet) from taxane chemotherapy. Researchers will track over 1,300 people with breast, lung, or ovarian cancer to see how age, gender, and other factors affect their risk. …
Matched conditions: STAGE III LUNG CANCER AJCC V8
Sponsor: SWOG Cancer Research Network • Aim: Knowledge-focused
Last updated Jun 03, 2026 12:04 UTC